Buy 5F-PB-22 for sale online from USA vendor
Table of Contents
- Introduction
- Chemistry of 5F-PB-22
- Pharmacology of 5F-PB-22
- Subjective Effects and Dosage Guidelines
- Physical Effects
- Perception Effects
- Cognitive Effects
- Combinational Effects and Toxicity
- Combinational Effects
- Toxicity and Harm Potential
- Tolerance, Addiction Potential, and Dangerous Interactions
- Tolerance and Addiction Potential
- Dangerous Interactions
- Legal Status
- Conclusion
Understanding 5F-PB-22: A Synthetic Cannabinoid
Introduction to 5F-PB-22
5F-PB-22, also referred to as 1-pentylfluoro-1H-indole-3-carboxylic acid 8-quinolinyl ester or 5F-QUPIC, belongs to the class of synthetic cannabinoids. These compounds act as agonists of the cannabinoid receptors, leading to effects akin to those of cannabis, albeit with variations. Despite its similarity to cannabis, there exists limited scientific literature detailing its pharmacology.
Pharmacological Properties and Consumption
When it comes to consumption, cannabinoids are typically smoked or vaporized for a swift onset of effects and rapid dissipation. However, unlike many cannabinoids, 5F-PB-22 exhibits oral activity when dissolved in lipids, thereby prolonging its duration of action. Notably, it is insoluble in water but can dissolve in ethanol and lipids, facilitating various consumption methods.
Health Risks and Concerns
While cannabis is generally considered relatively safe, the chronic abuse of synthetic cannabinoids like 5F-PB-22 poses severe health risks. Contrary to cannabis, synthetic cannabinoids have been linked to numerous fatalities and exhibit greater toxicity. Notably, there have been reports of five deaths associated with the use of 5F-PB-22 in the United States alone. Consequently, it is strongly advised against consuming this substance over prolonged periods or in excessive doses.
Understanding 5F-PB-22: Chemical Composition and Structure
Chemistry of 5F-PB-22
5F-PB-22, scientifically known as quinolin-8-yl 1-pentylfluoro-1H-indole-3-8-carboxylate, belongs to the class of synthetic indolecarboxylates. Its molecular structure comprises a substituted core indole, a common feature shared with other cannabinoid compounds such as PB-22, JWH-018, and AM2201. This synthetic cannabinoid is characterized as an ether (R-O-R') with two sub-units linked through an oxygen bridge. Specifically, the indole group of 5F-PB-22 is substituted at R5 with a fluoropentyl chain, akin to 5F-AKB48. Moreover, the indole core bears a carboxylic acid group at R3, with the terminal oxygen of this acid forming an ether bond with a quinoline group located at R8 of the heterocycle.
Pharmacological Insights into 5F-PB-22
Understanding the Pharmacology
While formal studies on 5F-PB-22 are lacking, its structure suggests a binding profile akin to other cannabinoids. It is presumed to share many in vivo properties with Δ9-THC, the primary psychoactive compound found in cannabis. However, the exact mechanisms underlying its interactions and how they contribute to the subjective experience of a cannabinoid high remain largely unclear.
Subjective Effects and Safety Considerations
Overview of Subjective Effects
Disclaimer: The effects mentioned below are derived from the Subjective Effect Index (SEI), which relies on anecdotal user reports and personal analyses from contributors of PsychonautWiki. It's essential to approach these effects with caution and skepticism.
It's important to note that the manifestation of these effects may not follow a predictable pattern, and higher doses are more likely to induce a broader spectrum of effects. Additionally, higher doses increase the likelihood of adverse effects, which can range from addiction to severe injury or even death.
Understanding 5F-PB-22: Chemistry and Pharmacology
Chemistry of 5F-PB-22
5F-PB-22, formally known as quinolin-8-yl 1-pentyfluoro-1H-indole-3-8-carboxylate, is categorized as a synthetic indolecarboxylate due to its substituted core indole structure. This core indole structure is shared with various other cannabinoid substances such as PB-22, JWH-018, and AM2201. Structurally, 5F-PB-22 is an ether compound (R-O-R') composed of two sub-units connected via an oxygen bridge. At the R5 position of the indole group, there is a substitution with a fluoropentyl chain, which is also found in 5F-AKB48. Additionally, the R3 position of the indole core features a carboxylic acid group, with its terminal oxygen bonded through an ether bond to a quinoline group located at R8 of the heterocycle.
Pharmacology of 5F-PB-22
Although formal studies on 5F-PB-22's pharmacology are lacking, structural analysis suggests that it likely shares a binding profile similar to other cannabinoids and may exhibit properties similar to Δ9-THC in vivo. However, the precise mechanisms of these interactions and how they contribute to the cannabinoid experience remain largely unknown.
Subjective Effects and Dosage Guidelines
Subjective Effects
Disclaimer: The following effects are based on anecdotal user reports and analyses from the Subjective Effect Index (SEI). They should be approached with caution and skepticism, as individual responses may vary. Additionally, higher doses increase the likelihood of experiencing the full range of effects, with potential for adverse effects including addiction, severe injury, or even death.
Dosage Guidelines
- Threshold: 1 mg
- Light: 1 - 3 mg
- Common: 3 - 5 mg
- Strong: 5 - 8 mg
- Heavy: 8 mg and above
Understanding the Physical and Visual Effects of 5F-PB-22
Physical Effects
- Spontaneous physical sensations: Users report experiencing a warm and soft pleasurable tingling sensation throughout their body, often described as a "body high." This sensation intensifies rapidly upon onset and reaches its peak before fading away.
- Sedation: The effects of 5F-PB-22 are highly sedating, leading users to feel relaxed, inclined to lie down, and sometimes to fall asleep, particularly at higher doses. Its sedative properties are noted to be comparable to JWH-018 and more pronounced than those of THC, JWH-073, THJ-018, AM-2201, or 5F-UR-144, albeit less than that of 5F-AKB48.
- Motor control loss: This substance induces partial to moderate suppression of motor control, escalating with dosage, though rarely leading to complete immobility.
- Appetite enhancement: Similar to many other cannabinoids, 5F-PB-22 increases appetite, colloquially known as "the munchies." Clinical studies attribute this effect to the activation of cannabinoid receptors responsible for regulating food intake in the hypothalamus.
- Dehydration: Commonly referred to as "cotton mouth," dehydration is a recognized side effect of 5F-PB-22 usage.
- Vasodilation: Cannabinoids like 5F-PB-22 decrease blood pressure by dilating blood vessels, leading to increased blood flow throughout the body. This effect can result in the expansion of arteries in the eyes and compensatory increases in heart rate.
- Pain relief: 5F-PB-22, like other cannabinoids, demonstrates pain-relieving properties through agonism of cannabinoid receptors CB1 and CB2.
Perception Effects
- Perception of bodily heaviness or lightness
- Changes in gravity: Users may experience vertigo, sensations of falling, or visual distortions resembling ripples in their field of vision, particularly at moderate doses. These effects tend to diminish with tolerance.
- Increased heart rate
Visual Effects
- Colour enhancement
- Acuity suppression
- Geometry: At moderate doses, 5F-PB-22 can induce closed-eye visuals and visual distortions, including geometric patterns. These visuals are reported to be milder and less defined compared to other cannabinoids such as JWH-018 or JWH-073.
Understanding the Cognitive Effects of 5F-PB-22
Cognitive Effects
- Emotion enhancement: Cannabinoids, including 5F-PB-22, are known to amplify existing emotions in a dose-dependent manner. This can lead to feelings of euphoria, intense laughter, heightened engagement in tasks, or conversely, anxiety and paranoia depending on the individual's mindset.
- Euphoria: Users may experience significant euphoria with 5F-PB-22, although it is generally less intense than with compounds like JWH-073.
- Thought connectivity: 5F-PB-22 is associated with fluid, abstract thinking rather than linear thought processes.
- Anxiety: While 5F-PB-22 is considered less anxiety-inducing than some cannabinoids like Δ9-THC or AM-2201, it may still provoke anxiety in some users.
- Paranoia: Like other cannabinoids, 5F-PB-22 can induce paranoia, particularly at high doses or with chronic use.
- Thought deceleration
- Conceptual thinking
- Mindfulness
- Analysis suppression
- Dream suppression
- Immersion enhancement
- Psychosis: Prolonged use of synthetic cannabinoids like 5F-PB-22 may elevate the risk of psychosis, especially in individuals predisposed to psychotic disorders.
- Increased music appreciation
Auditory Effects
- Enhancements
Understanding Combinational Effects and Toxicity of 5F-PB-22
Combinational Effects
- Psychedelics: Combining cannabinoids with psychedelics can intensify and prolong both visual and cognitive effects, requiring caution, especially for inexperienced users.
- Dissociatives: When used alongside dissociatives, cannabinoids may amplify effects such as geometry, euphoria, dissociation, and hallucinations.
- Alcohol: Mixing cannabinoids with alcohol can result in extreme nausea, dizziness, and alterations in perception. It's advised to consume cannabinoids before alcohol to mitigate potential adverse effects.
Toxicity and Harm Potential
- The toxicity and long-term health effects of 5F-PB-22 have not been thoroughly studied, and the exact toxic dosage remains unknown.
- Overdose can lead to physical discomfort, including heart palpitations, vertigo, and sedation, often causing anxiety or sleepiness.
- Several hospital reports and post-mortem analyses have linked 5F-PB-22 to fatalities, with five deaths reported in the United States alone.
- Prolonged usage of synthetic cannabinoids may increase the risk of mental illness and psychosis, particularly in individuals with pre-existing vulnerabilities.
Tolerance and Addiction Potential
- Chronic use of 5F-PB-22 can lead to moderate addiction and psychological dependence.
- Tolerance develops with repeated use, requiring higher doses to achieve the same effects. Withdrawal symptoms may occur upon cessation.
- Tolerance to 5F-PB-22 extends to other cannabinoids, resulting in reduced effectiveness across the board.
Dangerous Interactions
- Combining 5F-PB-22 with certain substances, including stimulants and psychedelics, can increase anxiety levels and the risk of negative experiences.
- Always research potential interactions before combining substances to avoid dangerous outcomes.
Legal Status
- 5F-PB-22 was developed to circumvent drug prohibition laws and remains legal in many parts of the world.
- It is controlled or banned in some countries, including China, Germany, Latvia, Switzerland, the United Kingdom, and the United States.
- China: Classified as a controlled substance as of October 2015.
- Germany: Controlled under the Narcotics Act as of December 13, 2014, making it illegal to possess, manufacture, import, export, buy, sell, procure, or dispense without a license.
- Latvia: Designated as a Schedule I controlled substance.
- Switzerland: Classified as a controlled substance under Verzeichnis D.
- United Kingdom: Listed as a Class B controlled substance under the third-generation synthetic cannabinoids generic definition since December 14, 2016, making it illegal to possess, produce, supply, or import.
- United States: Classified as a Schedule I controlled substance since January 2014, making it illegal to possess, distribute, or manufacture without proper authorization.
Conclusion
5F-PB-22, a synthetic cannabinoid, poses significant risks to users, including potential toxicity, addiction, and adverse interactions with other substances. Its legal status varies worldwide, with many countries implementing strict controls or outright bans due to safety concerns. Users should exercise caution and prioritize harm reduction practices when considering its consumption.
Frequently Asked Questions (FAQ)
1. What is 5F-PB-22?
- 5F-PB-22, also known as quinolin-8-yl 1-pentyfluoro-1H-indole-3-8-carboxylate, is a synthetic cannabinoid with a structure similar to other cannabinoids such as PB-22, JWH-018, and AM2201.
2. What are the physical effects of 5F-PB-22?
- The physical effects of 5F-PB-22 include spontaneous physical sensations, sedation, motor control loss, appetite enhancement, dehydration, vasodilation, and pain relief.
3. What are the cognitive effects of 5F-PB-22?
- The cognitive effects of 5F-PB-22 include emotion enhancement, euphoria, thought connectivity, anxiety, paranoia, thought deceleration, conceptual thinking, mindfulness, analysis suppression, and immersion enhancement.
4. Are there any dangerous interactions with 5F-PB-22?
- Yes, combining 5F-PB-22 with certain substances like stimulants or psychedelics can increase anxiety levels and the risk of negative experiences. It's essential to research potential interactions before combining substances.
5. What is the legal status of 5F-PB-22?
- The legal status of 5F-PB-22 varies by country. It is illegal or controlled in many countries, including China, Germany, the United Kingdom, and the United States.
6. Is 5F-PB-22 addictive?
- Chronic use of 5F-PB-22 can lead to moderate addiction and psychological dependence, requiring higher doses over time to achieve the same effects. Withdrawal symptoms may occur upon cessation.
7. What precautions should be taken when using 5F-PB-22?
- It is strongly recommended to practice harm reduction techniques when using 5F-PB-22, including starting with low doses, avoiding dangerous combinations, and being aware of potential risks and side effects.
To prepare the content, the following materials were used:
- FDA Substance Registration System
- Hazardous Substances Data Bank. National Library of Medicine. 28 August 2008. Retrieved 22 August 2014. 3,4-Methylenedioxymethamphetamine
- Liver transplant modulates gut microbial dysbiosis and cognitive function in cirrhosis. PDF . By HoChong Gilles, Scott C Matherly, Mohammed S Siddiqui, Puneet Puri...
- Differential impact of hyponatremia and hepatic encephalopathy on health-related quality of life and brain metabolite abnormalities in cirrhosis . By Jasmohan Bajaj
- An overview of alcohol and other drug issues
- Medicating the mind: a Kantian analysis of overprescribing psychoactive drugs B A Manninen
- The pharmacological basis of opioids Carla Ghelardini, Lorenzo Di Cesare Mannelli and Enrica Bianchi
- Ask Dr. Shulgin Online ARCHIVE: June 3, 2004
- Inhibition of plasma membrane monoamine transporters by β-ketoamphetamines. Nicholas V Cozzi, Michael KSievert, Alexander T Shulgin, Peyton JacobIII, Arnold Eruoho
- Schedules of Controlled Substances: Placement of Methylone Into Schedule I
- Bioanalysis of new designer drugs. Wohlfarth A, Weinmann W.
- New Psychoactive Substances (including synthetic cannabinoids, mephedrone, and more)
- Future Synthetic Drugs of Abuse. Donald A. Cooper. Drug Enforcement Administration McLean, Virginia
- Designer drugs: a medicinal chemistry perspective. F. Ivy Carroll Anita H. Lewin S. Wayne Mascarella Herbert H. Seltzman P. Anantha Reddy
- Synthetic cannabinoids in Europe
- Pharmacological Effects of MDMA in Man. By Enno Freye
- Drug Use in Relation to Outcome of Mammography Screening. von Euler-Chelpin M, Wu W, Vejborg and Lynge E
- DEA Drug Scheduling
- Electrophysiological Effects of Trace Amines on Mesencephalic Dopaminergic Neurons.Ada Ledonne, Nicola Berretta, Alessandro Davoli, Giada Ricciardo Rizzo, Giorgio Bernardi and Nicola Biagio Mercuri
- Electrophysiological evidence for a reciprocal interaction between amphetamine and cocaine-related drugs on rat midbrain dopaminergic neurons.Scarponi M, Bernardi G, Mercuri NB.
- Overdose of Drugs for Attention-Deficit Hyperactivity Disorder: Clinical Presentation, Mechanisms of Toxicity, and Management. Henry A. Spiller, author Hannah L. Hays Alfred Aleguas.
- Dose-dependent effectiveness of wheel running to attenuate cocaine-seeking: impact of sex and estrous cycle in rats. Peterson AB, Hivick DP, Lynch WJ.r.
- FDA Drug Safety Communication: Safety Review Update of Medications used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in children and young adults
- ADHD Medications and Risk of Serious Cardiovascular Events in Young and Middle-aged Adults
- Controlled Substances Act
- The Art of Drug Synthesis (Wiley Series on Drug Synthesis)
- Cannabis: domestic cultivation widespread
- A review of the influence of functional group modifications to the core scaffold of synthetic cathinones on drug pharmacokinetics